Distribution and Characteristics of Escherichia coli Clonal Group A

James R. Johnson,*† Andrew C. Murray,*† Michael A. Kuskowski,*† Sören Schubert,‡ Marie-Francoise Prère,§ Bertrand Picard,¶ Raul Colodner,# Raul Raz,#** and the Trans-Global Initiative for Antimicrobial Resistance Analysis (TIARA) Investigators2

Among 1,102 recent Escherichia coli clinical isolates, clonal group A was identified in 17 of 20 (U.S. and non-U.S.) geographic locales, mainly among U.S. isolates (9% vs. 3%; p < 0.001) and those resistant to trimethoprim-sulfamethoxazole (10% vs. 1.7%; p < 0.001). The extensive antimicrobial resistance and virulence profiles of clonal group A may underlie its recent widespread emergence.

The Study

The recently recognized Escherichia coli clonal group A (CGA) accounts for up to 50% of trimethoprim-sulfamethoxazole (TMP-SMZ)–resistant E. coli from U.S. women with acute uncomplicated cystitis and pyelonephritis (1–3). Available data show CGA to exhibit a stereotypical virulence factor (VF) profile and a conserved multidrug antimicrobial resistance phenotype, i.e., to ampicillin, chloramphenicol, streptomycin, sulfonamides, tetracycline, and trimethoprim (ACSSuTTp), which is conjugally transferable on a large plasmid (1,2). Together with CGA’s unusual O antigens (O11, O17, O73, and O77), these findings suggested that CGA represents a newly emerged virulent clonal group A (1,2). CGA’s homogeneity across geographic locales, and the indistinguishable pulsed-field gel electrophoresis (PFGE) profiles of clustered CGA isolates within 1 community (1), suggested recent and possibly ongoing dissemination, a novel paradigm for extraintestinal pathogenic E. coli (ExPEC) (4).

To date, CGA has been studied only within the United States, predominantly among women with uncomplicated urinary tract infections (UTI). Its occurrence in some locales has been questioned (5), and its antimicrobial susceptibility profile has been assessed for only 12 drugs (1,2,6). Accordingly, we sought to more fully define the global distribution, host range, virulence characteristics, and resistance phenotypes of CGA.

Twenty clinical microbiology laboratories (10 U.S., 10 non-U.S.) each provided approximately 25 consecutive TMP-SMZ–resistant and TMP-SMZ–susceptible E. coli isolates, except for 2 laboratories that provided resistant isolates only (Table 1). Isolates were distributed by specimen type (urine/other) and source (inpatient/outpatient). Antimicrobial drug–resistant and –susceptible isolates were collected approximately concurrently during 2001 from each site, except London (1999) (7) and Columbus (1999 and 2002). When available, data regarding specimen type and host gender, age, and inpatient/outpatient status were provided.

Phylogenetic group (A, B1, B2, or D) was defined by triplex polymerase chain reaction (PCR) (8). Group D isolates were defined as CGA if by random amplified polymorphic DNA (RAPD) analysis they resembled CGA controls with primers 1254 and 1290, or with one of these plus ≥2 of primers 1247, 1249, 1251, 1274, 1275, 1276, 1281, 1283, or 1291 (2). PFGE analysis used XbaI (1).

CGA isolates and (2:1) geographically matched controls selected randomly based on the local TMP-SMZ resistance prevalence were tested for 35 ExPEC-associated virulence markers and 13 papA alleles by PCR (2). Such typing predicts experimental in vivo virulence (9). Isolates were defined as ExPEC if positive for ≥2 of papA and/or papC, sfa/foc, afa/dra, iutA, and kpsM (10). The aggregate virulence score was the number of different virulence markers detected in an isolate, adjusted for multiple detection of certain operons.

O typing was carried out by the E. coli Reference Center (University Park, PA). O antigens O1, O2, O4, O6,

1Presented in part at the American Society for Microbiology 103rd General Meeting, May 18-22, 2003, Washington, D.C.
2The TIARA investigators include the following: Sacared Bodison (University of Maryland, College Park, MD), Franklin R. Cockerill, III (Mayo Clinic and Mayo Medical School, Rochester, MN), Clovis Arns da Cunha (Curitiba-PR, Brazil), Peter Echeverria and Sriluck Simasathien (Armed Forces Research Institute of Medical Sciences and Phramonkutkho Army Hospital, Bangkok, Thailand), Wim Gaastra (University of Utrecht, Utrecht, The Netherlands), Lucinda M.C. Hall (St Bartholomew’s and the Royal London School of Medicine and Dentistry, London, UK), Marina Klein (McGill University Health Centre, Montreal, Quebec, Canada), Hank A. Lockman (Battelle Memorial Institute, Columbus, OH), Imad Omer and Jane R. Schwebke (University of Alabama, Birmingham, AL), Guillem Prats (Hospital Vall d’Hebron, Barcelona, Spain), Robert M. Rakita (Virginia Mason Medical Center, Seattle, WA), Susan Rossman (Texas Childrens Hospital, Houston, TX), Ronald Schifman (Southern Arizona VA Medical Center, Tucson, AZ), Ronald Smith (Billings Clinic and Providence Medical Center, Billings, MT), and Patricia L. Winokur (VA Medical Center and University of Iowa, Iowa City, IA).
O7, O16, O18, O25, and O75 were considered UTI-associated (O-UTI) (10).

Susceptibility testing of the isolates to 30 drugs was carried out by broth microdilution (11) or disk diffusion (nitrofurantoin) (11), by using *E. coli* ATCC 25299 for reference and National Committee for Clinical Laboratory Standards (NCCLS)–specified interpretative criteria (12), except for kanamycin, spectinomycin, and streptomycin (resistant at MICs of >25 mg/L, >128 mg/L, and >8 mg/L, respectively). The aggregate resistance score was the number of different agents to which an isolate exhibited resistance.

Statistical analysis used a Fisher exact or a chi-square test for comparisons of proportions and the Mann-Whitney U test for comparisons of scores. Multiple variables were assessed as predictors of selected outcomes by multivariate logistic regression or multiple linear regression.

The 1,102 clinical *E. coli* isolates were divided evenly by U.S. and non-U.S. origin and TMP-SMZ resistance status (Table 2). Overall, phylogenetic group B2 predominated (44%), followed by group D (27%). Group D was significantly more prevalent among U.S. than non-U.S. isolates (34% vs. 21%; p < 0.001). TMP-SMZ–resistant isolates exhibited significant shifts from group B2 toward groups A, D, or both. The nearly 2-fold greater prevalence of group D

---

**Table 1. Sources of *Escherichia coli* clinical isolates and local prevalence of *E. coli* clonal group A (CGA) by trimethoprim-sulfamethoxazole (TMP-SMZ) phenotype**

| Location and type of institution | Patient population | Specimen type(s) | I/P or O/P† | Local TMP-SMZ resistance rate (%) | Total no isolates | TMP-SMZ–susceptible | TMP-SMZ–resistant | p value |
|----------------------------------|--------------------|------------------|-------------|-----------------------------------|-------------------|----------------------|-------------------|---------|
| Curtiba, Brazil                  | Mostly adults      | Urine, other     | I/P, O/P    | 33                                | 60                | 1/30 (3)             | 2/30 (7)          |         |
| University medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| Montreal, Canada                 | Mostly adults      | Urine, other     | I/P, O/P    | 33                                | 50                | 0/25 (0)             | 0/25 (0)          |         |
| University medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| London, England                  | Mostly adults      | Urine            | O/P         | 29                                | 46                | n.a.                 | 0/46 (0)          |         |
| Teaching hospital                |                    |                  |             |                                   |                   |                      |                   |         |
| Beest, France                    | Mostly adults      | Urine, blood     | I/P, O/P    | 30                                | 59                | 0/29 (0)             | 0/30 (0)          |         |
| University medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| Toulouse, France                 | Children           | Urine, other     | I/P, O/P    | 24                                | 50                | 0/25 (0)             | 5/25 (20)         | 0.05    |
| Children’s hospital              |                    |                  |             |                                   |                   |                      |                   |         |
| München, Germany                 | Mostly adults      | Unknown          | O/P         | 24                                | 55                | 0/27 (0)             | 2/28 (14)         |         |
| University medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| Atlula, Israel                   | Women              | Urine            | O/P         | 30                                | 100               | 1/51 (2)             | 3/49 (6)          |         |
| Outpatient clinic                |                    |                  |             |                                   |                   |                      |                   |         |
| Barcelona, Spain                 | Mostly adults      | Urine, other     | I/P, O/P    | 37                                | 74                | 2/30 (7)             | 0/44 (0)          |         |
| Private medical center           |                    |                  |             |                                   |                   |                      |                   |         |
| Göteborg, Sweden                 | Mostly adults      | Unknown          | O/P         | 10                                | 48                | 0/25 (0)             | 1/23 (4)          |         |
| University medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| Bangkok, Thailand                | Adults             | Urine, other     | O/P         | 67                                | 48                | 0/24 (0)             | 1/24 (4)          |         |
| Government hospital              |                    |                  |             |                                   |                   |                      |                   |         |
| Baltimore, MD, USA               | Mostly women       | Urine, other     | O/P         | 29                                | 62                | 2/24 (8)             | 7/38 (18)         |         |
| Student health center            |                    |                  |             |                                   |                   |                      |                   |         |
| Billings, MT, USA                | Mostly adults      | Urine, other     | I/P, O/P    | 11                                | 50                | 0/25 (0)             | 3/25 (12)         |         |
| Private medical center           |                    |                  |             |                                   |                   |                      |                   |         |
| Birmingham, AL, USA              | Mostly adults      | Urine, other     | I/P, O/P    | 18                                | 48                | 1/23 (4)             | 1/25 (4)          |         |
| University medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| Chicago, IL, USA                 | Mostly adults      | Urine            | O/P         | 24                                | 24                | NA                   | 7/24 (25)         |         |
| County medical center            |                    |                  |             |                                   |                   |                      |                   |         |
| Columbus, OH, USA                | Children           | Urine            | O/P, O/P    | 13                                | 59                | 0/33 (0)             | 6/26 (23)         | 0.005   |
| University medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| Iowa City, IA, USA               | Unknown            | Urine, other     | O/P         | 18                                | 58                | 0/27 (0)             | 4/31 (13)         |         |
| (Multiple)                       |                    |                  |             |                                   |                   |                      |                   |         |
| Houston, TX, USA                 | Children           | Urine            | O/P         | 36                                | 60                | 1/32 (3)             | 7/28 (25)         | 0.02    |
| Children’s medical center        |                    |                  |             |                                   |                   |                      |                   |         |
| Rochester, MN, USA               | Mostly adults      | Urine            | O/P         | 16                                | 54                | 1/28 (4)             | 0/26 (0)          |         |
| Private medical center           |                    |                  |             |                                   |                   |                      |                   |         |
| Seattle, WA, USA                 | Adults             | Unknown          | O/P         | 15                                | 50                | 0/24 (0)             | 6/26 (23)         | 0.02    |
| Teaching hospital                |                    |                  |             |                                   |                   |                      |                   |         |
| Tucson, AZ, USA                  | Men                | Unknown          | O/P         | 25                                | 47                | 0/34 (0)             | 2/13 (15)         |         |
| Veterans’ medical center         |                    |                  |             |                                   |                   |                      |                   |         |

†Eighteen centers contributed both susceptible and resistant isolates (total, 47 to 100 isolates each; median, 55). Two centers contributed only resistant isolates (Chicago, IL, USA: 24 isolates; London, England: 46 isolates). Specimen type was known for 55 of the CGA isolates and was urine for 42, nonurine for 13 (10 blood, 1 tracheal aspirate, 1 fecal, 1 unspecified nonurine).

*Isolates were collected in 2001 for all sites except London, England (1999), and Columbus, OH, USA (1999 for susceptible isolates and part of resistant isolates; 2002 for remaining resistant isolates).*
among TMP-SMZ-resistant isolates reversed, for U.S.
isolates, the “B2 > D” pattern of susceptible isolates.

By RAPD analysis, 23% of group D isolates (6% overall) represented CGA (Table 2). CGA was strongly
associated with TMP-SMZ resistance (10% of resistant isolates, 1.7% of susceptible: $p<0.001$) and a U.S. origin
(9% vs. 3%; $p<0.001$). CGA accounted for 15% of U.S.
TMP-SMZ–resistant isolates and 5% of those from abroad
($p<0.001$), but for a similarly low proportion of U.S. (2%) and non-U.S. (1.5%) susceptible isolates. According to
multivariate logistic regression analysis, after accounting
for TMP-SMZ resistance and U.S. origin, none of the other
source variables (specimen type and host gender, age, and
inpatient/outpatient status) was significantly associated
with CGA status or appreciably altered the association of
TMP-SMZ resistance or U.S. origin with CGA status (not
shown).

CGA occurred in all but 3 locales (1–10 isolates per
locale), accounting for up to 29% of local resistant isolates
(median, 9.5%) (Table 1). CGA was highly prevalent
(20%–25%) among resistant isolates from the 3 pediatric
centers (Columbus, Houston, and Toulouse) and the veterans'
hospital (Tucson). Toulouse exhibited the highest non-
U.S. CGA prevalence, whereas nearby Brest lacked CGA
(Table 1). CGA accounted for 29% of the ostensibly non-
clonal (5) TMP-SMZ–resistant isolates from Chicago.
Consistent with this, XbaI PFGE profiles of 6 Chicago and
2 reference CGA isolates were highly similar (Figure 1).

CGA isolates differed significantly from controls, according to almost all characteristics analyzed; they were
significantly enriched with the O11, O17, and O77 anti-
gens, certain VF s (F16 papA allele, papAHCEF G, papG
allele II, i ha, iutA, kpsM II, traT, and ompT), and ExPEC
status, but lacked other traits (Figure 2). Aggregate viru-
lence scores were similar for CGA and controls (median,
8.0) but were less diverse for CGA (range 5–9, vs. 1–13).

By multivariate logistic regression, both CGA status and
phylogenetic group B2 were significant independent pre-
dictors of ExPEC status, with CGA exhibiting an odds ratio
(OR) of 21.9 (95% confidence interval [CI], 6.1–78.2; $p<0.001$) and group B2 an OR of 2.4 (CI, 1.7–3.4; $p<0.001$).
Additionally, by multiple linear regression, CGA status
(standardized regression coefficient $[\beta] = 0.57$; $p<0.001$)
and group B2 status ($\beta = 0.596$; $p<0.001$) predicted VF
score better than did O-UTI ($\beta = 0.32$; $p = 0.002$).

Antimicrobial resistance phenotypes were compared
between CGA isolates and a subset of the controls, which
had been selected to provide an unbiased distribution of
TMP-SMZ resistance (Figure 2). CGA exhibited a higher
prevalence of resistance to 10 individual drugs, any drug,
and ACSSuTTP, whereas controls exhibited a low but
measurable prevalence of resistance to 7 drugs to which all
CGA isolates were susceptible. Accordingly, resistance

---

**Table 2. Prevalence of phylogenetic groups and *Escherichia coli* clonal group A (CGA) according to locale and resistance phenotype**

| *E. coli* group | Total (N = 1,102) | United States (N = 512) | Non–United States (N = 590) |
|----------------|------------------|-------------------------|-----------------------------|
|                | Overall          | Susceptible (n = 516)   | Resistant (n = 566)         | p value† |
| ECOR A         | 168 (15)         | 65 (13)                 | 103 (18)                    | 0.02     |
| ECOR B1        | 143 (13)         | 70 (14)                 | 73 (12)                     | NS       |
| ECOR B2        | 483 (44)§        | 277 (54)§               | 210 (35)                    | <0.001   |
| ECOR D         | 298 (27)§        | 98 (19)§                | 200 (34)                    | <0.001   |
| CGA            | 68 (6)           | 9 (1.7)                 | 59 (10)                     | <0.001   |

*ECOR, E. coli reference*  
†For prevalence of group B2 (versus group D) within same column; $p \leq 0.01$, McNemar's test.
§For prevalence of group D among U.S. (vs. non-U.S.) susceptible isolates; $p = 0.005$ (Fisher exact test).
#For prevalence of group D among U.S. (vs. non-U.S.) resistant isolates; $p < 0.001$ (Fisher exact test).

---

**Escherichia coli** Clonal Group A

![Figure 1](https://www.cdc.gov/eid/)

**Figure 1. XbaI pulsed-field gel electrophoresis profiles of *Escherichia coli* clonal group A (CGA) isolates and *E. coli* O157:H7. Lane numbers are shown below the gel image. Six CGA isolates from Chicago and 2 reference CGA isolates are shown. Lane numbers are shown below the gel image. Six CGA isolates from Chicago and 2 reference CGA isolates are shown.**
scores were significantly higher for CGA than controls (median 8.0 [range 1–11] vs. 5.5 [range 0–15]; p = 0.001). Among TMP-SMZ–resistant isolates, TMP-SMZ MICs ranged from 32/608 mg/L to >520/9,880 mg/L; 61% of resistant isolates had MICs ≥520/9,880 mg/L. CGA accounted for 67% of this highly resistant population (p = 0.01 vs. controls).

The U.S. and non-U.S. CGA isolates exhibited only 2 statistically significant differences for VF profiles, O antigens, and resistance phenotypes, with *iroN* (p = 0.03) and absence of *ompT* (p = 0.008) associated with non-U.S. isolates.

**Conclusions**

We found that the recently described *E. coli* CGA is globally but heterogeneously distributed and more prevalent within the United States than abroad. Clonal group A affects diverse host populations (including inpatients, outpatients, adults, children, men, and women), infects urinary tract and nonurinary tract sites, is strongly associated with TMP-SMZ resistance (particularly high-level resistance), and exhibits a robust virulence profile suggesting enhanced extraintestinal virulence. This combination of resistance and virulence may account for CGA’s recent emergence as a broadly disseminated “epidemic clone” (1–3,6,13,14).

The greater overall prevalence of CGA within the United States suggests a U.S. origin for CGA. However, it also could reflect more rapid clonal expansion within the United States due to enhanced dissemination or more favorable conditions for outgrowth, including possibly less competition from other potential occupants of the same niche(s). The variable prevalence of CGA among even closely situated locales, both within the United States and abroad, might reflect true geographic heterogeneity, versus locale-specific differences in patient populations, selection criteria, and collection intervals. Studies that compare well-defined, homogeneous, concurrent populations from different locales are needed.

The new evidence of CGA as a prominent TMP-SMZ–resistant pathogen among children and veterans extends the known host range of CGA, consistent with a recent report of CGA as a community-wide TMP-SMZ-resistant pathogen in Denver, Colorado (6). This finding illustrates CGA’s pathogenic versatility.

That 29% of the TMP-SMZ–resistant isolates from Chicago, Illinois, proved to be CGA and resembled reference CGA isolates by PFGE, despite a previous PFGE-based assessment of nonclonality (5), illustrates the limitations of conventional PFGE analysis as a screen for CGA. We have developed a CGA-specific PCR assay, based on a single nucleotide polymorphism within *fumC*, to provide improved screening for CGA (15).
CGA’s robust, highly homogeneous consensus VF profile (F16 papa allele, papG allele II, iutA, kpsM II, traT, and ompT) suggests considerable extraintestinal virulence potential, an inference supported by experimental data indicating that CGA is able to compete successfully with classic group B2-derived pathogens in a mouse UTI model (J.R. Johnson, unpub. data). Determination of which VFs of CGA contribute most to pathogenicity may identify future targets for preventive interventions.

In our study, antimicrobial resistance was more extensive and, with TMP-SMZ, more potent for CGA than controls. These factors may be contributing to CGA’s global emergence. Conceivably, high-level TMP-SMZ resistance could allow CGA to out-compete even other TMP-SMZ–resistant strains. CGA’s resistance involved primarily older agents, whereas fluoroquinolone and cephalosporin resistance was confined to controls. However, the emergence of fluoroquinolone resistance within the closely related O15:K52:H1 clonal group (2,13) suggests that this potential exists also for CGA.

The study’s strengths include large population, broad geographic sampling, matching of CGA and control isolates, and extensive range of traits analyzed. Limitations include the heterogeneous inclusion criteria, gaps in global surveillance, possible type I errors from multiple comparisons, and limited sampling per locale.

In summary, we found CGA to be a globally disseminated, multidrug-resistant clonal group of pathogenic *E. coli* with a broad range of human hosts. Although more prevalent within the United States than abroad, CGA exhibits characteristic O antigens, resistance markers, and virulence traits wherever encountered. Further study is needed of the origins, virulence mechanisms, geographic distribution, clinical associations, and modes of dissemination of CGA.

**Acknowledgments**

We thank Dave Prentiss for preparing the figures; Sheldon Finver, Abby Gajewski, and Timothy T. O’Bryan for invaluable laboratory assistance; the clinical microbiology laboratory of the Minneapolis VA Medical Center for assisting with antimicrobial susceptibility testing; and Amee Manges and Lee Riley for providing strain SEQ102.

This material is based upon work supported by Office of Research and Development, Medical Research Service, Department of Veterans Affairs, and by Bayer Inc., Merck, and Procter & Gamble (J.R.J.). J.R.J. has received grants, honoraria, or both, from Bayer, Merck, Ortho-McNeill, Procter and Gamble, and Wyeth-Ayerst.

Dr. Johnson is professor of medicine and director of the Infectious Diseases Fellowship Program at the University of Minnesota, and head of the molecular epidemiology laboratory at the Minneapolis VA Medical Center. His research focuses on the molecular epidemiology, ecology, evolution, and virulence of extraintestinal pathogenic and antimicrobial-resistant *E. coli*.

**References**

1. Manges AR, Johnson JR, Foxman B, O’Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant *Escherichia coli* clonal group. N Engl J Med. 2001;345:1007–13.

2. Johnson JR, Manges AR, O’Bryan TT, Riley LR. A disseminated multi-drug resistant clonal group of extraintestinal pathogenic *Escherichia coli* as a cause of pyelonephritis. Lancet. 2002;359:2249–51.

3. Manges AR, Dietrich PS, Riley LW. Multidrug-resistant *Escherichia coli* clonal groups causing community-acquired pyelonephritis. Clin Infect Dis. 2004;38:329–34.

4. Stamm WE. An epidemic of urinary tract infections? N Engl J Med. 2001;345:1055–7.

5. Petrof EO, Schwartz DN, Quinnn JP. Urinary tract infections and a multidrug-resistant *Escherichia coli* clonal group [letter]. N Engl J Med. 2002;346:535.

6. Burman WJ, Breese PE, Murray BE, Singh KV, Batal HA, MacKenzie TA, et al. Conventional and molecular epidemiology of trimethoprim-sulfamethoxazole resistance among urinary *Escherichia coli* isolates. Am J Med. 2003;115:358–64.

7. Enne VI, Livermore DM, Stephens P, Hall LCM. Persistence of sulphonamide resistance in *Escherichia coli* in the UK despite national prescribing restriction. Lancet. 2001;357:1325–8.

8. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the *Escherichia coli* phylogenetic group. Appl Environ Microbiol. 2000;66:4555–8.

9. Johnson JR, Kuskowski M, Denamur E, Elion J, Picard B. Clonal origin of virulence factors, and virulence [letter and reply]. Infect Immun. 2000;68:424–5.

10. Johnson JR, Murray AC, Gajewski A, Sullivan M, Shippes P, Kuskowski MA, et al. Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic *Escherichia coli* from retail chicken products. Antimicrob Agents Chemother. 2003;47:2161–8.

11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Vol. 23, no. 2. M7-A6. Wayne (PA): The Committee; 2003.

12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement. Vol. 24, no. 1. M100-S14. Wayne (PA): The Committee; 2004.

13. Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/or extended spectrum cephalosporins and cephapirin among *Escherichia coli* isolates from animals and humans. J Infect Dis. 2003;188:759–68.

14. Johnson JR, Russo TA. “Uropathogenic” *Escherichia coli* as agents of diverse non-urinary-tract extraintestinal infections. J Infect Dis. 2002;186:859–64.

15. Johnson JR, Owens, Manges A, Riley L. Rapid and specific detection of *Escherichia coli* clonal group A by gene-specific PCR. J Clin Microbiol. 2004;42:2618–22.